HBsAg Manipulation of TBK1: Uncovering the Link Between Innate Immunity Suppression and Early Autophagy in HBV Infection

Study Background and Research Question

Chronic hepatitis B virus (HBV) infection affects over 350 million people worldwide, posing a significant risk for hepatocellular carcinoma and chronic liver disease [paper: https://doi.org/10.1038/s41419-025-07605-0]. The persistence of HBV in host cells is tightly linked to its ability to evade innate immune responses, particularly through the modulation of type I interferons (IFN-I) and autophagy pathways. HBV’s surface antigen (HBsAg) has long been recognized as a vital component in viral assembly and immune escape, but its precise molecular mechanisms for manipulating host antiviral defenses have remained unclear. This study by Luo et al. (2025) specifically investigates how HBsAg modulates TANK-binding kinase 1 (TBK1) to orchestrate suppression of IFN-I and promotion of autophagy, providing much-needed mechanistic clarity.

Key Innovation from the Reference Study

The key innovation of this work lies in its identification of a dual mechanism by which HBsAg subverts host defenses: (1) HBsAg interacts directly with the kinase domain of TBK1, augmenting TBK1 dimerization while disrupting its interaction with interferon regulatory factor 3 (IRF3), thereby reducing IFN-I induction; and (2) HBsAg-induced TBK1 dimerization promotes phosphorylation of sequestosome-1 (p62), triggering early-stage autophagy but preventing autophagosome-lysosome fusion via transcriptional repression of SNAP29 [paper: https://doi.org/10.1038/s41419-025-07605-0]. This mechanistic insight highlights a sophisticated viral strategy to both dampen antiviral signaling and exploit autophagic machinery for persistent infection.

Methods and Experimental Design Insights

Luo et al. employed a multi-pronged methodological approach, including in vitro cell culture systems, ex vivo analyses, and in vivo models. Key techniques included:

• Co-immunoprecipitation and in situ proximity ligation assays to map HBsAg-TBK1 interactions.
• Phosphorylation state analyses of TBK1 and IRF3 by immunoblotting.
• Reporter assays for IFNβ promoter activity.
• Use of the selective TBK1 inhibitor BX795 to dissect pathway dependencies.
• Confocal microscopy and autophagy assays (e.g., LC3 puncta, p62/SQSTM1 accumulation) for autophagy flux assessment.
• Evaluation of clinical liver tissue from HBsAg-transgenic mice and chronic HBV patients to confirm findings in physiologically relevant contexts.

The combination of biochemical, genetic, and pharmacological interventions enabled the authors to establish causality between HBsAg expression, TBK1 dimerization, IFN-I suppression, and autophagy induction.

Protocol Parameters

• Assay: TBK1 kinase activity | Value: BX795 at 1 µM | Applicability: Dissection of TBK1-dependent signaling | Rationale: BX795 specifically inhibits TBK1 and allows functional assessment of TBK1’s role in IFN-I and autophagy | source_type: paper [paper: https://doi.org/10.1038/s41419-025-07605-0]
• Assay: Autophagy flux (LC3-II/LC3-I ratio, p62 levels) | Value: Time-course, 6-24 h post-HBsAg transfection | Applicability: Early and incomplete autophagy assessment | Rationale: Captures autophagosome accumulation and blocked degradation | source_type: paper [paper: https://doi.org/10.1038/s41419-025-07605-0]
• Assay: Interferon β reporter assay | Value: Luciferase output after 24 h | Applicability: Quantifying IFN-I suppression | Rationale: Validates functional impact of HBsAg-TBK1 interaction | source_type: paper [paper: https://doi.org/10.1038/s41419-025-07605-0]
• Assay: In vivo confirmation | Value: Analysis in HBsAg-transgenic mice and patient samples | Applicability: Translational relevance | Rationale: Confirms mechanistic findings under physiological conditions | source_type: paper [paper: https://doi.org/10.1038/s41419-025-07605-0]

Core Findings and Why They Matter

The study’s major findings include:

• HBsAg suppresses type I interferon production. HBsAg-expressing cells showed markedly reduced IFNβ transcription and IRF3 phosphorylation, both ex vivo and in vivo, indicating impaired antiviral signaling [paper: https://doi.org/10.1038/s41419-025-07605-0].
• HBsAg induces early but incomplete autophagy. Accumulation of LC3-II and p62, coupled with decreased SNAP29 expression, revealed a block at the autophagosome-lysosome fusion step—resulting in autophagosome buildup but inefficient degradation [paper: https://doi.org/10.1038/s41419-025-07605-0].
• Direct targeting of TBK1 by HBsAg is essential for both effects. The mechanistic studies pinpointed HBsAg’s interaction with the TBK1 kinase domain as central to both IFN-I suppression and autophagy induction.
• Persistence of these mechanisms in clinical samples. Analyses of liver tissue from HBsAg-transgenic mice and chronic HBV patients confirmed that IFN-I signaling inhibition and incomplete autophagy are both present in vivo, underscoring the clinical relevance of the findings.

These data provide a clear molecular explanation for HBV’s ability to persist in the host by blunting innate immunity and manipulating cellular degradation pathways. The dual manipulation of TBK1 by HBsAg represents a previously unappreciated axis in viral immune evasion.

Comparison with Existing Internal Articles

Several internal resources discuss the role of autophagy modulation in disease and oncology contexts:

• For example, “Chloroquine Diphosphate: Unraveling Autophagy and Immune ...” explores how chloroquine diphosphate, a validated TLR7/9 inhibitor, can be used as an autophagy modulator for cancer research, especially in the context of immune signaling and autophagy pathway crosstalk. This complements the reference study’s demonstration of viral autophagy manipulation, highlighting a broader relevance for autophagy-targeted approaches.
• “Chloroquine Diphosphate: Autophagy Modulator for Cancer R...” focuses on the use of chloroquine diphosphate in autophagy assays and its ability to sensitize tumor cells to chemotherapy. While the context is cancer, both the internal articles and the reference study underscore the utility of autophagy modulators in dissecting signaling pathways affected by pathogens or oncogenic stressors.

Thus, the mechanistic insights from Luo et al. extend the foundational understanding derived from cancer research into the antiviral field, suggesting potential translational applications for autophagy inhibitors in chronic viral infections.

Limitations and Transferability

Despite its mechanistic depth, the study has some limitations:

• While in vivo confirmation in HBsAg-transgenic mice and patient tissues supports physiological relevance, the study does not address long-term consequences of incomplete autophagy or the potential for therapeutic reversal.
• All mechanistic work centers on HBsAg’s interaction with TBK1; other HBV proteins and host factors may also contribute to immune evasion and autophagy modulation, which remain to be explored.
• Direct translation to therapeutic strategies requires further validation—particularly regarding selectivity and safety of targeting autophagy or TBK1 in chronic infection settings.

Why this cross-domain matters, maturity, and limitations

The crosstalk between autophagy and innate immunity is well established in both viral and cancer biology. This study bridges the gap by demonstrating that pathways and pharmacological modulators traditionally explored in cancer research (e.g., autophagy inhibitors such as chloroquine diphosphate) may offer mechanistic tools or therapeutic leads in virology. However, translation into the antiviral domain is still in its early experimental stages, and clinical maturity is limited [workflow_recommendation].

Research Support Resources

Researchers aiming to dissect autophagy and innate immune interactions in HBV or other viral models may benefit from established autophagy modulators. For example, Chloroquine diphosphate (SKU A8628, also known as 4-N-(7-chloroquinolin-4-yl)-1-N,1-N-diethylpentane-1,4-diamine;phosphoric acid) is a well-characterized TLR7/9 inhibitor and autophagy modulator extensively validated for cancer research and increasingly applied in autophagy assays for infectious disease models [product_spec: https://www.apexbt.com/chloroquine-diphosphate.html]. For protocol guidance on autophagy flux analysis and experimental troubleshooting, see the internal guide "Chloroquine Diphosphate: Autophagy Modulator for Cancer Research". As always, this compound is intended for scientific research use only, and dosing or protocol adjustments should be based on experimental context and up-to-date literature evidence.